The University of Southampton
University of Southampton Institutional Repository

Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo

Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo
Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo
Background: It has been argued that measurement of outcome in panic disorder should not be limited to monitoring the number of panic attacks, but should include all domains that affect patient quality of life. Methods: Data from a randomized prospective comparison of escitalopram, citalopram, and placebo in patients with DSM-IV panic disorder were analyzed with regard to measurements of impairment of quality of life. The subscales of the Panic and Agoraphobia Scale (P&A) (Panic Attacks, Agoraphobic Avoidance, Anticipatory Anxiety, Functional and Social Disability, and Worries about Health) and the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) were analyzed. Results: Treatment with escitalopram was associated with significant improvement on all 5 subscales of the P&A. Citalopram was significantly different from placebo in 3 subscales. Escitalopram and citalopram were significantly better than placebo in improving quality of life (measured by the total score of the Q-LES-Q Scale). Escitalopram was superior to placebo on 12 of 16 items of the Q-LES-Q, while citalopram was superior on 7 items. Conclusion: The P&A scale was more robust than measurement of panic frequency in differentiating medication from placebo. Escitalopram treatment was associated with improvement on all assessed domains that impair quality of life in panic disorder. Measurement of clinical improvement should not be solely based on panic attack frequency, but should also include assessment of a broad range of domains that affect patient quality of life.
satisfaction, social anxiety disorder, health, placebo, disorders, severity, efficacy, double-blind, agoraphobia, multicenter, dsm-iv, escitalopram, validity, population, major depressive disorder
0176-3679
152-156
Bandelow, B.
f90459a9-1f40-40bb-bd92-d4c1e4cbb9f4
Stein, D.J.
908f8238-f5e4-4ea1-9f19-9be45feea5b6
Dolberg, O.T.
a3e324dd-5ade-49d6-99f4-00ef6ad78542
Andersen, H.F.
23022aa3-3faf-4e24-848a-526652a6c893
Baldwin, D.S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Bandelow, B.
f90459a9-1f40-40bb-bd92-d4c1e4cbb9f4
Stein, D.J.
908f8238-f5e4-4ea1-9f19-9be45feea5b6
Dolberg, O.T.
a3e324dd-5ade-49d6-99f4-00ef6ad78542
Andersen, H.F.
23022aa3-3faf-4e24-848a-526652a6c893
Baldwin, D.S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e

Bandelow, B., Stein, D.J., Dolberg, O.T., Andersen, H.F. and Baldwin, D.S. (2007) Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. Pharmacopsychiatry, 40 (4), 152-156.

Record type: Article

Abstract

Background: It has been argued that measurement of outcome in panic disorder should not be limited to monitoring the number of panic attacks, but should include all domains that affect patient quality of life. Methods: Data from a randomized prospective comparison of escitalopram, citalopram, and placebo in patients with DSM-IV panic disorder were analyzed with regard to measurements of impairment of quality of life. The subscales of the Panic and Agoraphobia Scale (P&A) (Panic Attacks, Agoraphobic Avoidance, Anticipatory Anxiety, Functional and Social Disability, and Worries about Health) and the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) were analyzed. Results: Treatment with escitalopram was associated with significant improvement on all 5 subscales of the P&A. Citalopram was significantly different from placebo in 3 subscales. Escitalopram and citalopram were significantly better than placebo in improving quality of life (measured by the total score of the Q-LES-Q Scale). Escitalopram was superior to placebo on 12 of 16 items of the Q-LES-Q, while citalopram was superior on 7 items. Conclusion: The P&A scale was more robust than measurement of panic frequency in differentiating medication from placebo. Escitalopram treatment was associated with improvement on all assessed domains that impair quality of life in panic disorder. Measurement of clinical improvement should not be solely based on panic attack frequency, but should also include assessment of a broad range of domains that affect patient quality of life.

Full text not available from this repository.

More information

Published date: July 2007
Keywords: satisfaction, social anxiety disorder, health, placebo, disorders, severity, efficacy, double-blind, agoraphobia, multicenter, dsm-iv, escitalopram, validity, population, major depressive disorder

Identifiers

Local EPrints ID: 62307
URI: https://eprints.soton.ac.uk/id/eprint/62307
ISSN: 0176-3679
PURE UUID: b7fe654c-2ab5-4324-84d2-05b6c4b5d7f3

Catalogue record

Date deposited: 12 Sep 2008
Last modified: 13 Mar 2019 20:27

Export record

Contributors

Author: B. Bandelow
Author: D.J. Stein
Author: O.T. Dolberg
Author: H.F. Andersen
Author: D.S. Baldwin

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×